Vanguard Group
KPRX icon

Vanguard Group’s Kiora Pharmaceuticals KPRX Stock Holding History

Vanguard Group’s Portfolio KPRX Stock Details KPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$65.2K Buy
33,091
+12,176
+58% +$27.8K ﹤0.01% 4214
2025
Q3 		$58.6K Buy
+20,915
New +$57.5K ﹤0.01% 4282
2024
Q2 		– Sell
-2,730
Closed -$17.3K – 4427
2024
Q1 		$17.3K Hold
2,730
– – ﹤0.01% 4403
2023
Q4 		$12.8K Buy
2,730
+1,563
+134% +$8.12K ﹤0.01% 4469
2023
Q3 		$5.96K Hold
1,167
– – ﹤0.01% 4526
2023
Q2 		$6.75K Hold
1,167
– – ﹤0.01% 4540
2023
Q1 		$35.1K Buy
+1,167
New +$43.6K ﹤0.01% 4498
2022
Q3 		– Sell
-187
Closed -$31K – 4606
2022
Q2 		$31K Sell
187
-27
-13% -$4.52K ﹤0.01% 4602
2022
Q1 		$48K Sell
214
-207
-49% -$54.1K ﹤0.01% 4619
2021
Q4 		$229K Hold
421
– – ﹤0.01% 4543
2021
Q3 		$341K Buy
421
+66
+19% +$56.1K ﹤0.01% 4430
2021
Q2 		$465K Buy
355
+234
+193% +$364K ﹤0.01% 4281
2021
Q1 		$217K Buy
121
+56
+86% +$122K ﹤0.01% 4248
2020
Q4 		$115K Buy
65
+33
+103% +$45.5K ﹤0.01% 4133
2020
Q3 		$46K Hold
32
– – ﹤0.01% 4069
2020
Q2 		$56K Buy
+32
New +$60K ﹤0.01% 4026
2019
Q3 		– Sell
-30
Closed -$39K – 4158
2019
Q2 		$39K Buy
30
+6
+25% +$8.86K ﹤0.01% 4127
2019
Q1 		$40K Hold
24
– – ﹤0.01% 4073
2018
Q4 		$61K Buy
24
+3
+14% +$6.92K ﹤0.01% 4052
2018
Q3 		$36K Hold
21
– – ﹤0.01% 4141
2018
Q2 		$61K Buy
21
+7
+50% +$19.7K ﹤0.01% 4092
2018
Q1 		$28K Sell
14
-36
-72% -$156K ﹤0.01% 4082
2017
Q4 		$287K Hold
50
– – ﹤0.01% 3867
2017
Q3 		$314K Buy
50
+4
+9% +$25.5K ﹤0.01% 3835
2017
Q2 		$339K Buy
46
+1
+2% +$9.87K ﹤0.01% 3797
2017
Q1 		$626K Buy
45
+22
+96% +$247K ﹤0.01% 3704
2016
Q4 		$204K Buy
23
+9
+64% +$78.6K ﹤0.01% 3887
2016
Q3 		$130K Buy
14
+2
+17% +$21.4K ﹤0.01% 3957
2016
Q2 		$166K Hold
12
– – ﹤0.01% 3972
2016
Q1 		$197K Buy
12
+10
+500% +$154K ﹤0.01% 3962
2015
Q4 		$35K Buy
+2
New +$32.2K ﹤0.01% 4154

Other funds holding KPRX

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Vanguard Group's KPRX Position: Q4 2025 in Review

Vanguard Group increased its Kiora Pharmaceuticals (KPRX) stake by 58% in Q4 2025, buying an estimated $27.8K and bringing the position to 33,091 shares worth $65.2K. The position accounts for ﹤0.01% of the portfolio, ranked #4214.

Vanguard Group first reported a position in KPRX in Q4 2015 and has held it in 31 quarters since. The position peaked at $626K in Q1 2017. 19 funds tracked by Wall St. Rank hold KPRX as of Q4 2025.

  • Vanguard Group held 33,091 shares of Kiora Pharmaceuticals worth $65.2K as of Q4 2025.
  • Vanguard Group bought 12,176 Kiora Pharmaceuticals shares in Q4 2025, an estimated $27.8K.
  • Kiora Pharmaceuticals made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #4214 holding.
  • Vanguard Group first reported a position in Kiora Pharmaceuticals in Q4 2015 and has held it in 31 quarters since.
  • Vanguard Group's Kiora Pharmaceuticals position peaked at $626K in Q1 2017.
  • 19 funds tracked by Wall St. Rank held Kiora Pharmaceuticals as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.